Prashant Dogra is an Assistant Professor in the Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences at the University of Southern California, where he also serves as Associate Director of the Center for Quantitative Drug and Disease Modeling. He leads interdisciplinary research integrating multiscale mechanistic modeling, quantitative systems pharmacology, and data science to predict in vivo disease dynamics, optimize drug delivery, and support therapeutic development. His work advances the fields of cancer therapeutics, infectious disease vaccines, and nanomedicine by providing innovative modeling tools to accelerate clinical translation. He is particularly enthusiastic about integrating artificial intelligence with mechanistic modeling approaches and currently serves as Principal Investigator on an NIH R01 grant focused on developing AI-integrated mechanistic models to advance nanoparticle-based drug delivery systems.

Eleni Caratzas (Karatza), MSc, PhD, is a Principal Scientist II at J&J IM/Janssen R&D. She completed her undergraduate and master’s degrees in pharmacy at the University of Athens, Greece. Following her studies, she started working as a scientist-consultant at a pharmaceutical consulting firm. After earning her PhD, she started her postdoctoral fellowship with the UNC Eshelman School of Pharmacy and GSK. Dr. Karatza has published over 25 peer-reviewed articles and book chapters in the field of clinical pharmacology and pharmacometrics. An active ISoP member since 2018, she has supported various ISoP and ACoP initiatives and she was awarded the ISoP Unsung Hero Award in 2024.

Stacey Tannenbaum, PhD, FISoP is a scientist and leader in Model Informed Drug Development, and principal at SJTPharm LLC. She is currently a Consultant and Coach to the MIDD community, supporting the development of leadership, communication, and change management skills.

Her previous roles include VP of Scientific Engagement at Metrum Research Group, and Pharmacometrics science and leadership at Novartis and Astellas. Stacey earned a BSE in Biomedical Engineering (Duke University), a PhD in Pharmaceutical Sciences and Applied Mathematics (University of Arizona), and a post-doctoral fellowship at the Center for Drug Development Science (Georgetown University). During her 25+ years as a PKPD scientist in Pharma and consulting, Stacey contributed to multiple drug development programs and successful submissions. Some of the outcomes of her work were optimization of dosing for future trials and labels, prediction of efficacy and safety with confidence, design of smarter studies and identification of key covariates, and bridging across populations, such as from healthy subjects to patients, and adults to children. As she transitioned from individual contributor into leadership roles, her expertise expanded beyond the science itself to include: championing science communication and soft skills development within technical teams, building infrastructure and implementing best practices for efficient and reproducible MIDD, guiding partners in translating clinical needs into strategic and model-informed solutions, and mentoring and training the next generation of leaders.

Stacey has had a significant impact on the global Pharmacometrics community. She co-founded ISoP, serving as its first President, and is an ISoP Fellow and Leadership Award recipient. Stacey co-founded the ACoP and was conference chair for the first three events; she remains an active volunteer in both ISoP and ACoP. She is the Executive Committee chair for WCoP, and is the chair of the Quantitative Pharmacology Network at ASCPT. She served as a board member of AAPS, chaired the AAPS M&S Focus Group, and was the co-chair for the AAPS Forum for Connecting Predictive Modelers. Stacey also co-founded the networking group Modeling and Simulation Applications in Clinical Pharmacotherapy (MoSAiC), now ISoP-NJ/NY/PA.

Martin obtained his PhD in Pharmacometrics from Uppsala University. He has 20+ years of drug development experience in areas such as metabolic disorders, autoimmune disease, infectious disease, hematological disorders etc. In 2012 Martin co-founded the consulting company Pharmetheus AB. In the consultant role he has been engaged as strategic advisor on behalf of multiple clients and acted as the main responsible consultant for 50+ pharmacometric data analysis projects on behalf of more than 20 different clients. The projects have ranged from pre-clinical translational projects to submission ready large-scale phase III PKPD analysis. These analyses have among other things contributed to 5+ successful NDA filings. 

Gianluca obtained an M.Sc. in Biomedical engineering from University of Bologna, Italy, and Ph.D. in Bioengineering from the New University of Lisbon, Portugal. He is an expert in quantitative systems pharmacology (QSP) modelling spanning therapeutic areas such as oncology and immuno-inflammation. He has worked as a Senior Modeler at the Fondazione Microsoft Research – University of Trento Centre for Computational and Systems Biology. During his time at Pharmetheus he has among other things contributed to the development of a QSP framework for drug immunogenicity following subcutaneous administration.

Xiaobin Li is the Programming Director of Clinical Pharmacology Modeling & Simulation Programming and Business Excellence at GSK, with over 20 years of experience in Pharmacometric Programming and tool development. Currently she is serving on the ISoP PMX Programming Special Interest Group (SIG) Steering Committee and co-leading its Data Visualization Working Group. 

Srinivas Bachina is currently working in AstraZeneca as Director CPQP programming, leading internal Pharmacometric programming. He has over 20 years of experience in Pharmacometric Programming and currently involved in ISOP Data Visualization working group. 

Erin has over 17 years of experience in pharmacometric programming and currently leads a team at Bristol Myers Squibb, dedicated to supporting pharmacometric analysis dataset preparation. Her interests and expertise lie in creating and implementing efficiencies through standards and automation, and she enjoys training and developing new pharmacometric programmers. Erin's leadership extends to her co-lead roles in the Data Quality, Visualization and Reporting, and Introduction to Pharmacometrics Analysis Dataset Programming working groups within the ISOP PMx Data Programming Special Interest Group.

Jing Liu, PhD, is currently a Senior Director of Clinical Pharmacology at Pfizer Research and Development. Dr. Liu is an influential leader in innovative model-informed drug discovery and development with over 25+ years of experience across multiple disease areas, drug modalities and all stages of drug development. She has authored 150+ scientific manuscripts, abstracts and book chapters, and has been an invited speaker/Co-Chair at international scientific meetings including scientific exchanges on accelerating pediatric drug development with PMDA in Japan and NMPA in China. Dr. Liu is currently a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Board of Directors, and has held leadership roles on various committees, task forces, and ASCPT Network and Community. She is also a founding member of International Society of Pharmacometrics (ISOP) and the Abstract Chair for 2014 American Conference of Pharmacometrics (ACOP). Dr. Liu is the Past-Chair and a member of the International Consortium for Innovation and Quality (IQ) Clinical Pharmacology Pediatrics Working Group to advance innovative and efficient pediatric drug development.

Phyllis is a pharmacometrician in the Clinical Pharmacology Modeling & Simulation group at Genentech in South San Francisco. Before joining Genentech in 2017, Phyllis worked at Bristol-Myers Squibb, obtained her PhD in Pharmaceutical Sciences from Auburn University and was a postdoctoral fellow at University of Southern California's Biomedical Simulations Resource (BMSR).  More recently, Phyllis received an MPH from Imperial College London.  She specializes in population PK, exposure-response, tumor growth inhibition-overall survival, and model-based meta-analysis.

Dr. Cédric Scherer (he/him) is a computational ecologist turned independent data visualization professional. Combining research expertise with a passion for data and design, he helps organizations, research teams, and businesses communicate insights through engaging visualizations, reports, and presentations. Specializing in bespoke, code-driven designs—from clear and effective to artistic and unconventional—Cédric has created visualizations across various disciplines and regularly teaches data visualization principles, R, and ggplot2.

Rong is a research scientist at Certara USA Inc’s Data Sciences Division Phoenix NLME group. His responsibility involves maintaining, improving, and developing the existing and new computational and statistical algorithms for Phoenix NLME software. Rong got his nuclear physics PhD at Arizona State University in 2020. The PhD focused on large-scale quantum Monte Carlo simulations. Prior to join Certara in 2023, Rong was a postdoctoral research fellow at Children’s Hospital Los Angeles where he developed high performance parametric and nonparametric algorithms for population pharmacokinetics/pharmacodynamics (PK/PD) modeling.